Exosome-mediated intercellular delivery of CRISPR/Cas9 targeting the hepatitis B virus genome
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) protein 9 (CRISPR/Cas9) technology was adapted from the adaptive immunity mechanism of bacteria. It recognizes specific DNA sequences through a single guide RNA (gRNA) and guides the Cas9 protein, which has endonuclease activity, to cut the DNA double strands. Compared with gene editing technologies such as zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN), the improved CRISPR/Cas9 system consists of only two parts, the gRNA and the Cas9 protein, and has advantages such as simple operation, short experimental cycle and low cost.
To determine whether single guide RNA (gRNA) and Cas9 protein exist in exosomes secreted by cells transfected with CRISPR/Cas9 expression plasmids, and to explore whether the CRISPR/Cas9 system can achieve editing of target genes in surrounding cells through intercellular transfer of exosomes, Wang Jie, Chen Ran and Lu Fengmin of Peking University transfected CRISPR/Cas9 expression plasmids into HuH7 cells, collected the cell culture supernatant, concentrated and purified the exosomes by differential centrifugation, measured the morphology and particle size of the exosomes by electron microscopy and a Malvern laser scattering particle size analyzer, and detected gRNA and Cas9 protein levels by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively. (2) HuH7 cells respectively transfected with 1.2x hepatitis B virus (HBV) expression plasmids and HBV-specific CRISPR/Cas9 expression plasmids were co-cultured. After 2 days, intracellular HBV DNA was extracted, PCR-amplified and sequenced.
The results showed that the exosomes produced by HuH7 cells transfected with CRISPR/Cas9 expression plasmids not only contained full-length gRNA and Cas9 protein, but could also transfer their gene editing function between cells, achieving destruction of the HBV genome in surrounding cells.
As a potential delivery system, exosomes can transfer the gene editing function of the CRISPR/Cas9 system between cells by carrying functional gRNA and Cas9 protein. This phenomenon also suggests that when using the CRISPR/Cas9 system for gene therapy, it is necessary to consider the potential impact of exosomes carrying gRNA and Cas9 protein on surrounding and distant tissue cells. Source: Chinese Journal of Hepatology.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.